SCHEMBL26202204

SCHEMBL26202204

CC(=O)NCCc1c[nH]c2cc(C)cc(NC(C)=O)c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 15/20 0.56
▸ MTNR1B P49286 15/20 0.56
▸ CYP1A2 P05177 6/20 0.50
▸ CYP3A4 P08684 4/20 0.50
▸ CYP2D6 P10635 4/20 0.50
▸ BLM P54132 3/20 0.50
▸ NOTUM Q6P988 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ IDO1 P14902 1/20 0.50
▸ SPR P35270 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25381610 0.86 MTNR1A (0.57) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL26203714 0.83 MTNR1A (0.57) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL26202017 0.76 MTNR1A (0.54) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL24460220 0.75 MTNR1A (0.80) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL25295069 0.74 MTNR1A (0.61) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL29437233 0.74 MTNR1A (0.61) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL25381235 0.73 HTR2B (0.65) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL26202172 0.73 MTNR1A (0.60) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL25380931 0.73 MTNR1A (0.60) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL31543697 0.72 MTNR1A (1.00) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270768-A1 MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING Enveric Biosciences Canada Inc. (CA) 2023-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270768-A1 MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING CNR2, CNR1, HTR1B MTNR1A 927/4885MTNR1B 122/4885CYP1A2 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback